The advantage of this kind of therapy is that it allows you to attack intracellular antigens, which are presented on the surface by means of HLA molecules. So you’re not restricted to surface-only antigens as the classic bispecifics or CAR-T cell approaches are. The downside of that is that these kind of approaches only work in the context of a given HLA-A allele, so most of the compounds developed thus far focus on HLA-A0201, which is present in 40 to 50 percent of the western population, so the most frequent one...
The advantage of this kind of therapy is that it allows you to attack intracellular antigens, which are presented on the surface by means of HLA molecules. So you’re not restricted to surface-only antigens as the classic bispecifics or CAR-T cell approaches are. The downside of that is that these kind of approaches only work in the context of a given HLA-A allele, so most of the compounds developed thus far focus on HLA-A0201, which is present in 40 to 50 percent of the western population, so the most frequent one. It is less frequent in other races and ethnicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.